EGFR and non-small cell lung carcinoma: Although therapeutics targeted to activated EGFR have contributed significantly to the management of NSCLC, long-term treatment with these drugs often leads to the development of drug resistance and tumor relapse.9 The IAPs are key regulators of apoptosis and are often overexpressed in tumors that are drug-resistant.